Society of Hematologic Oncology Annual Meeting (SOHO) | Conference

Venetoclax Plus FLAG-IDA Elicits High and Durable Responses in Newly Diagnosed AML

September 9th 2021

The addition of venetoclax to fludarabine, cytarabine, idarubicin and G-CSF resulted in high complete response rates and enables a high consolidative allogeneic transplantation rate in patients with newly diagnosed acute myeloid leukemia.

Dr. Coombs on the Efficacy Results of the BRUIN Study With Pirtobrutinib in CLL

September 9th 2021

Catherine Callaghan Coombs, MD, discusses the efficacy results of the ongoing phase 1/2 BRUIN study with pirtobrutinib in chronic lymphocytic leukemia.

Targeted Therapies, Immunotherapies Slated to Propel T-cell ALL Treatment Paradigm Forward

September 8th 2021

The cure rate for patients with T-cell acute lymphoblastic leukemia has improved dramatically over the past few decades, with outcomes becoming comparable to what is observed in those with B-cell acute lymphoblastic leukemia.

Dr. Cortes on Emerging Therapies in CML

September 8th 2021

Jorge E. Cortes, MD, discusses emerging therapies in chronic myeloid leukemia.

Novel, Emerging Approaches Set the Stage for Advancement in cGVHD

September 8th 2021

In recent years, significant advances have been made regarding the treatment of patients with chronic graft-vs-host disease, with investigators developing an understanding of the pathophysiology of the disease, as well as how to integrate novel treatment modalities.

SYMPATICO Evaluates Frontline Ibrutinib and Venetoclax Combo in MCL

September 14th 2020

The open-label arm of the 3-part phase 3 SYMPATICO trial is evaluating the combination of ibrutinib and venetoclax in previously untreated patients with mantle cell lymphoma.

Novel Combos Are Shaking Up the CLL Landscape

September 15th 2019

The rise of oral targeted therapies and novel combinations is transforming the paradigm for the frontline treatment of patients with chronic lymphocytic leukemia regardless of age, and ongoing phase III trials are likely to generate more modifications.

Myelofibrosis Management Makes Strides With JAK Inhibitors, But Work Remains

September 15th 2019

Laura C. Michaelis, MD, discusses the currently approved JAK inhibitors and the future landscape for myelofibrosis, as well as treatment considerations for graft-versus-host disease.

Tisagenlecleucel Maintains Efficacy in Real-World Setting

September 15th 2019

Early results from a prospective postmarketing assessment showed that tisagenlecleucel induced responses similar to those seen in pivotal trials for children and adolescents with B-cell acute lymphoblastic leukemia and adults with diffuse large B-cell lymphoma.

Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell Lymphoma

September 14th 2019

Basem William, MD, MRCP, FACP, discusses the preliminary results of the phase II trial of brentuximab vedotin and lenalidomide in relapsed/refractory cutaneous and peripheral T-cell lymphomas.

Dr. Westin on Response Rates in the JULIET Trial for DLBCL

September 14th 2019

Jason Westin, MD, discusses patient responses with relapsed/refractory diffuse large B-cell lymphoma in the JULIET trial who were treated with tisagenlecleucel.

Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

September 14th 2019

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Update Spotlights Tisagenlecleucel Developments in DLBCL

September 14th 2019

Tisagenlecleucel maintained strong rates of response and duration of response in adults with relapsed/refractory diffuse large B-cell lymphoma, according to the latest findings from the phase II JULIET study presented at the 2019 SOHO Annual Meeting.

Despite Challenges, Targeted Cellular Therapies Continue to Be Explored in AML

September 13th 2019

John F. DiPersio, MD, PhD, discusses the challenges in research surrounding targeted cellular therapies for acute myeloid leukemia

Checkpoint Inhibition Before HSCT Improves PFS Without Increasing Toxicity in R/R Hodgkin Lymphoma

September 13th 2019

The use of checkpoint inhibitors prior to haploidentical stem cell transplantation improved progression-free survival and reduced the risk for relapse for patients with relapsed or refractory Hodgkin lymphoma, according to results from a retrospective study presented at the 2019 SOHO Annual Meeting.

Dr. Maloney on the Registry for Real World Data of CAR T-Cell Therapy in ALL

September 13th 2019

David G. Maloney, MD, PhD, discusses the initiative to use the Center for International Blood and Marrow Transplant Research Cellular Therapy Registry to report real world experience of tisagenlecleucel CAR T cells targeting CD19 in patients with acute lymphoblastic leukemia.

JAK Inhibition Continues to Push Progress in Myelofibrosis

September 13th 2019

Ruben Mesa, MD, discusses the JAKARTA and JAKARTA-2 studies and the implications their data have on the field of myelofibrosis.

Dr. Michaelis on Fedratinib in Myelofibrosis Treatment

September 13th 2019

Laura C. Michaelis, MD, discusses the integration of fedratinib into the treatment sequence of myelofibrosis.

Dr. Kebriaei on Eligibility for Stem Cell Transplant in ALL

September 13th 2019

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

New Approaches Are Needed to Boost CAR Therapies in ALL

September 13th 2019

Novel strategies are needed to enhance the efficacy of CAR T-cell therapies in patients with acute lymphoblastic leukemia, including new constructs that target more than 1 antigen.